Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence

被引:34
作者
Zhou, Xingwu [1 ,2 ,3 ]
Qu, Moyuan [1 ,2 ,4 ]
Tebon, Peyton [1 ,2 ]
Jiang, Xing [1 ,2 ,5 ]
Wang, Canran [1 ,2 ]
Xue, Yumeng [1 ,2 ]
Zhu, Jixiang [1 ,2 ,6 ]
Zhang, Shiming [1 ,2 ]
Oklu, Rahmi [7 ]
Sengupta, Shiladitya [8 ]
Sun, Wujin [1 ,2 ]
Khademhosseini, Ali [1 ,2 ,3 ,9 ,10 ,11 ]
机构
[1] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Ctr Minimally Invas Therapeut, Calif NanoSyst Inst, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Dept Chem & Biomol Engn, Los Angeles, CA 90095 USA
[4] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu 610041, Peoples R China
[5] Nanjing Univ Chinese Med, Sch Nursing, Nanjing 210023, Peoples R China
[6] Guangzhou Med Univ, Sch Basic Med Sci, Dept Biomed Engn, Guangzhou 511436, Peoples R China
[7] Mayo Clin, Div Vasc & Intervent Radiol, Minimally Invas Therapeut Lab, Phoenix, AZ 85054 USA
[8] Harvard Med Sch, Harvard MIT, Div Hlth Sci & Technol, Boston, MA 02115 USA
[9] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA
[10] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA
[11] Terasaki Inst Biomed Innovat, Los Angeles, CA 90064 USA
基金
美国国家卫生研究院;
关键词
artificial intelligence; cancer immunotherapy; drug screening; high-throughput screening; tissue engineering; ACQUIRED-RESISTANCE; PD-1; BLOCKADE; TUMOR-CELLS; T-CELLS; ORGANOID CULTURES; CTLA-4; IMMUNE CELLS; VACCINES; GENERATION; CHALLENGES;
D O I
10.1002/advs.202001447
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Immunotherapy is a class of promising anticancer treatments that has recently gained attention due to surging numbers of FDA approvals and extensive preclinical studies demonstrating efficacy. Nevertheless, further clinical implementation has been limited by high variability in patient response to different immunotherapeutic agents. These treatments currently do not have reliable predictors of efficacy and may lead to side effects. The future development of additional immunotherapy options and the prediction of patient-specific response to treatment require advanced screening platforms associated with accurate and rapid data interpretation. Advanced engineering approaches ranging from sequencing and gene editing, to tumor organoids engineering, bioprinted tissues, and organs-on-a-chip systems facilitate the screening of cancer immunotherapies by recreating the intrinsic and extrinsic features of a tumor and its microenvironment. High-throughput platform development and progress in artificial intelligence can also improve the efficiency and accuracy of screening methods. Here, these engineering approaches in screening cancer immunotherapies are highlighted, and a discussion of the future perspectives and challenges associated with these emerging fields to further advance the clinical use of state-of-the-art cancer immunotherapies are provided.
引用
收藏
页数:21
相关论文
共 195 条
  • [1] Microfluidic models for adoptive cell-mediated cancer immunotherapies
    Adriani, Giulia
    Pavesi, Andrea
    Tan, Anthony T.
    Bertoletti, Antonio
    Thiery, Jean Paul
    Kamm, Roger D.
    [J]. DRUG DISCOVERY TODAY, 2016, 21 (09) : 1472 - 1478
  • [2] A new age in functional genomics using CRISPR/Cas9 in arrayed library screening
    Agrotis, Alexander
    Ketteler, Robin
    [J]. FRONTIERS IN GENETICS, 2015, 6
  • [3] PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
    Alsaab, Hashem O.
    Sau, Samaresh
    Alzhrani, Rami
    Tatiparti, Katyayani
    Bhise, Ketki
    Kashaw, Sushil K.
    Iyer, Arun K.
    [J]. FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [4] From big data analysis to personalized medicine for all: challenges and opportunities
    Alyass, Akram
    Turcotte, Michelle
    Meyre, David
    [J]. BMC MEDICAL GENOMICS, 2015, 8
  • [5] Becht E, 2020, J IMMUNOL, V204
  • [6] Hydrogel bioprinted microchannel networks for vascularization of tissue engineering constructs
    Bertassoni, Luiz E.
    Cecconi, Martina
    Manoharan, Vijayan
    Nikkhah, Mehdi
    Hjortnaes, Jesper
    Cristino, Ana Luiza
    Barabaschi, Giada
    Demarchi, Danilo
    Dokmeci, Mehmet R.
    Yang, Yunzhi
    Khademhosseini, Ali
    [J]. LAB ON A CHIP, 2014, 14 (13) : 2202 - 2211
  • [7] Microfluidic organs-on-chips
    Bhatia, Sangeeta N.
    Ingber, Donald E.
    [J]. NATURE BIOTECHNOLOGY, 2014, 32 (08) : 760 - 772
  • [8] Organoid Models of Human and Mouse Ductal Pancreatic Cancer
    Boj, Sylvia F.
    Hwang, Chang-Il
    Baker, Lindsey A.
    Chio, Iok In Christine
    Engle, Dannielle D.
    Corbo, Vincenzo
    Jager, Myrthe
    Ponz-Sarvise, Mariano
    Tiriac, Herve
    Spector, Mona S.
    Gracanin, Ana
    Oni, Tobiloba
    Yu, Kenneth H.
    van Boxtel, Ruben
    Huch, Meritxell
    Rivera, Keith D.
    Wilson, John P.
    Feigin, Michael E.
    Oehlund, Daniel
    Handly-Santana, Abram
    Ardito-Abraham, Christine M.
    Ludwig, Michael
    Elyada, Ela
    Alagesan, Brinda
    Biffi, Giulia
    Yordanov, Georgi N.
    Delcuze, Bethany
    Creighton, Brianna
    Wright, Kevin
    Park, Youngkyu
    Morsink, Folkert H. M.
    Molenaar, I. Quintus
    Rinkes, Inne H. Borel
    Cuppen, Edwin
    Hao, Yuan
    Jin, Ying
    Nijman, Isaac J.
    Iacobuzio-Donahue, Christine
    Leach, Steven D.
    Pappin, Darryl J.
    Hammell, Molly
    Klimstra, David S.
    Basturk, Olca
    Hruban, Ralph H.
    Offerhaus, George Johan
    Vries, Robert G. J.
    Clevers, Hans
    Tuveson, David A.
    [J]. CELL, 2015, 160 (1-2) : 324 - 338
  • [9] Microfluidics: A New Tool for Modeling Cancer-Immune Interactions
    Boussommier-Calleja, Alexandra
    Li, Ran
    Chen, Michelle B.
    Wong, Siew Cheng
    Kamm, Roger D.
    [J]. TRENDS IN CANCER, 2016, 2 (01): : 6 - 19
  • [10] Human primary liver cancer-derived organoid cultures for disease modeling and drug screening
    Broutier, Laura
    Mastrogiovanni, Gianmarco
    Verstegen, Monique M. A.
    Francies, Hayley E.
    Gavarro, Lena Morrill
    Bradshaw, Charles R.
    Allen, George E.
    Arnes-Benito, Robert
    Sidorova, Olga
    Gaspersz, Marcia P.
    Georgakopoulos, Nikitas
    Koo, Bon-Kyoung
    Dietmann, Sabine
    Davies, Susan E.
    Praseedom, Raaj K.
    Lieshout, Ruby
    IJzermans, Jan N. M.
    Wigmore, Stephen J.
    Saeb-Parsy, Kourosh
    Garnett, Mathew J.
    van der Laan, Luc J. W.
    Huch, Meritxell
    [J]. NATURE MEDICINE, 2017, 23 (12) : 1424 - +